Monte Rosa Therapeutics, Inc. (GLUE), a developer of novel molecular glue degrader-based medicines, said that it has priced its underwritten public offering of 11.125 million shares at $24 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1.375 million shares at $23.999 per pre-funded warrant.
Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1.875 million shares at $24 per share.
The company anticipates gross proceeds of around $300 million from the offering, excluding any exercise of the underwriters' option to purchase additional shares.
All of the shares and pre-funded warrants are to be sold by Monte Rosa.
The offering is expected to close on or about January 12.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.